Finalist
GlobeIN Education: Transforming Haemoglobinopathy Practice in the Cell Editing Era
by ApotheCom for Vertex Pharmaceuticals
Summary of work
Haemoglobinopathies, including sickle cell disease (SCD) and transfusion dependent β-thalassaemia (TDT), are rare debilitating red cell disorders, which negatively impact all elements of physical and emotional health. Despite standard of care, haemoglobinopathies have a devastating impact on quality of life. Regulatory approval of the world’s first cell editing therapy has given hope to patients and multidisciplinary teams (MDTs). However, in this era of innovation, are they ready to embark on this journey into the unknown?
GlobeIN was designed based on a thorough situational analysis and patient journey mapping exercise alongside an MDT of international haemoglobinopathy experts to raise awareness of haemoglobinopathies; enhance knowledge of state-of-the-art management; and improve service design, by forging connections between teams and inspiring confidence to support earlier referral, ultimately increasing opportunities for patients.
To date, GlobeIN has successfully launched a myriad of bespoke educational initiatives for all members of the MDT. Providing opportunities for accredited live education; access to a portal complete with bite-sized local language resources; and connecting, for the first time, haematologists and transplant experts to support practice change. Substantial knowledge gain in those participating has been observed, as well as increased MDT discussions and connections as assessed in 12-month follow-up.
Judges’ comments
Apothecom and Vertex Pharmaceuticals have created a comprehensive programme with demonstrable long-term impact. The entry itself was well written and had some great supporting materials, and the one-year following attendance piece stood out to the judges. The rationale and strategy were really strong, and the implementation was excellent.
